Immunovant Fiscal Q1 2027 Results: IMVT-1402 Spending Widens Net Loss

Immunovant (NASDAQ: IMVT) reported a fiscal Q1 2027 net loss of $153.2 million, compared with $120.6 million a year earlier, while basic and diluted loss per share widened to $0.75 from $0.71. Higher spending on IMVT-1402 trials and contract manufacturing drove the increase, even as general and administrative costs declined; quarter-end cash totaled $797.8 million. All six announced IMVT-1402 development programs remained on their disclosed timelines.

Core financial results

Immunovant’s cost structure reflects the expansion of its lead clinical program. R&D expense increased approximately 41% year over year, outweighing a 32% reduction in G&A expense and lifting total operating expenses by 26%.

The GAAP net loss widened approximately 27%, but the per-share loss increased by a smaller 5.6%. Weighted-average shares outstanding rose about 20% to 205.5 million, limiting the change in loss per share relative to the increase in the overall loss.

The R&D increase primarily came from IMVT-1402 clinical trial activity and contract manufacturing costs, partly offset by lower spending as Immunovant winds down its batoclimab trials. The G&A decline reflected lower personnel expenses, professional fees, market research costs, and information technology spending.

IMVT-1402 pipeline and upcoming milestones

Development plans remained on track across Graves’ disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, difficult-to-treat rheumatoid arthritis, Sjögren’s disease, and cutaneous lupus erythematosus. The next disclosed milestones begin in the second half of calendar 2026.

These timelines make the CLE data and D2T RA update the most immediate clinical events, followed by the Graves’ disease and myasthenia gravis readouts in 2027.

Cash position and balance sheet

Cash and cash equivalents declined by $104.3 million, or approximately 11.6%, from March 31 to June 30, 2026. Immunovant said the remaining $797.8 million provides runway to a potential commercial launch of IMVT-1402 in Graves’ disease under its current operating plan.

The higher share count is also relevant to per-share results. Common shares outstanding increased by approximately 2.3 million during the quarter, while the year-over-year increase in weighted-average shares reduced the extent to which the larger net loss appeared in loss per share.

Recent insider transactions

The supplied transaction data show that the latest 10 reported entries consisted of seven sales and three derivative-security exercises. All were reported as direct transactions, and the table preserves the source’s reported value field without drawing conclusions about insiders’ outlook.

Risks investors should monitor

• Clinical execution and readout risk: The company’s disclosed milestones depend on trial enrollment, execution, and data availability. Early or preliminary results may not predict later-stage outcomes, and future trials may not confirm expected safety or efficacy.
• Dependence on IMVT-1402: Immunovant’s development and commercialization strategy is heavily concentrated on IMVT-1402. Delays, unfavorable data, or regulatory setbacks could affect multiple planned indications and the company’s broader operating plan.
• Rising development costs and future funding: R&D expense increased approximately 41% as clinical and manufacturing activity expanded. Although management expects current cash to fund operations through a potential Graves’ disease launch under its current plan, the release also states that additional capital will be required to fund operations and advance IMVT-1402 through development.
• Manufacturing and supply-chain exposure: Contract manufacturing is already contributing to higher R&D spending. The company also identified tariffs, geopolitical tensions, and macroeconomic conditions as potential sources of disruption to its supply chain and clinical timelines.

Summary

Immunovant’s fiscal first quarter was defined by higher IMVT-1402 development spending, which outweighed lower overhead costs and widened the net loss. The company retains $797.8 million in cash and says its six announced clinical programs remain on schedule. The next major points to monitor are the CLE topline data and D2T RA update expected in the second half of 2026, together with the pace of R&D spending and changes in the cash balance.